Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with alzheimer dementia: The cache county dementia progression study

Joann T. Tschanz, Chris D. Corcoran, Sarah Schwartz, Katherine Treiber, Robert C. Green, Maria C. Norton, Michelle M Mielke, Kathleen Piercy, Martin Steinberg, Peter V. Rabins, Jeanne Marie Leoutsakos, Kathleen A. Welsh-Bohmer, John C S Breitner, Constantine G. Lyketsos

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

OBJECTIVES: Progression of Alzheimer dementia (AD) is highly variable. Most estimates derive from convenience samples from dementia clinics or research centers where there is substantial potential for survival bias and other distortions. In a population-based sample of incident AD cases, we examined progression of impairment in cognition, function, and neuropsychiatric symptoms, and the influence of selected variables on these domains. DESIGN: Longitudinal, prospective cohort study. SETTING: Cache County (Utah). PARTICIPANTS: Three hundred twenty-eight persons with a diagnosis of possible/probable AD. MEASUREMENTS: Mini-Mental State Exam (MMSE), Clinical Dementia Rating sum-of-boxes (CDR-sb), and Neuropsychiatric Inventory (NPI). RESULTS: Over a mean follow-up of 3.80 (range: 0.07-12.90) years, the mean (SD) annual rates of change were-1.53 (2.69) scale points on the MMSE, 1.44 (1.82) on the CDR-sb, and 2.55 (5.37) on the NPI. Among surviving participants, 30% to 58% progressed less than 1 point per year on these measures, even 5 to 7 years after dementia onset. Rates of change were correlated between MMSE and CDR-sb (r =-0.62, df = 201, p < 0.001) and between the CDR-sb and NPI (r = 0.20, df = 206, p < 0.004). Female subjects (LR χ2 = 8.7, df = 2, p = 0.013) and those with younger onset (likelihood ratio [LR] χ2 = 5.7, df = 2, p = 0.058) declined faster on the MMSE. Although one or more apolipoprotein E ε 4 alleles and ever use of FDA-approved antidementia medications were associated with initial MMSE scores, neither was related to the rate of progression in any domain. CONCLUSIONS: A significant proportion of persons with AD progresses slowly. The results underscore differences between population-based versus clinic-based samples and suggest ongoing need to identify factors that may slow the progression of AD.

Original languageEnglish (US)
Pages (from-to)532-542
Number of pages11
JournalAmerican Journal of Geriatric Psychiatry
Volume19
Issue number6
DOIs
StatePublished - Jun 2011
Externally publishedYes

Fingerprint

Dementia
Alzheimer Disease
Population
Equipment and Supplies
Apolipoprotein E4
Cognition
Cohort Studies
Alleles
Prospective Studies
Survival
Research

Keywords

  • Alzheimer dementia
  • Alzheimer disease
  • cognition
  • decline
  • dementia
  • neuropsychiatric symptoms
  • progression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology

Cite this

Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with alzheimer dementia : The cache county dementia progression study. / Tschanz, Joann T.; Corcoran, Chris D.; Schwartz, Sarah; Treiber, Katherine; Green, Robert C.; Norton, Maria C.; Mielke, Michelle M; Piercy, Kathleen; Steinberg, Martin; Rabins, Peter V.; Leoutsakos, Jeanne Marie; Welsh-Bohmer, Kathleen A.; Breitner, John C S; Lyketsos, Constantine G.

In: American Journal of Geriatric Psychiatry, Vol. 19, No. 6, 06.2011, p. 532-542.

Research output: Contribution to journalArticle

Tschanz, JT, Corcoran, CD, Schwartz, S, Treiber, K, Green, RC, Norton, MC, Mielke, MM, Piercy, K, Steinberg, M, Rabins, PV, Leoutsakos, JM, Welsh-Bohmer, KA, Breitner, JCS & Lyketsos, CG 2011, 'Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with alzheimer dementia: The cache county dementia progression study', American Journal of Geriatric Psychiatry, vol. 19, no. 6, pp. 532-542. https://doi.org/10.1097/JGP.0b013e3181faec23
Tschanz, Joann T. ; Corcoran, Chris D. ; Schwartz, Sarah ; Treiber, Katherine ; Green, Robert C. ; Norton, Maria C. ; Mielke, Michelle M ; Piercy, Kathleen ; Steinberg, Martin ; Rabins, Peter V. ; Leoutsakos, Jeanne Marie ; Welsh-Bohmer, Kathleen A. ; Breitner, John C S ; Lyketsos, Constantine G. / Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with alzheimer dementia : The cache county dementia progression study. In: American Journal of Geriatric Psychiatry. 2011 ; Vol. 19, No. 6. pp. 532-542.
@article{628b73e7c8ca46c0b317981f92f4062b,
title = "Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with alzheimer dementia: The cache county dementia progression study",
abstract = "OBJECTIVES: Progression of Alzheimer dementia (AD) is highly variable. Most estimates derive from convenience samples from dementia clinics or research centers where there is substantial potential for survival bias and other distortions. In a population-based sample of incident AD cases, we examined progression of impairment in cognition, function, and neuropsychiatric symptoms, and the influence of selected variables on these domains. DESIGN: Longitudinal, prospective cohort study. SETTING: Cache County (Utah). PARTICIPANTS: Three hundred twenty-eight persons with a diagnosis of possible/probable AD. MEASUREMENTS: Mini-Mental State Exam (MMSE), Clinical Dementia Rating sum-of-boxes (CDR-sb), and Neuropsychiatric Inventory (NPI). RESULTS: Over a mean follow-up of 3.80 (range: 0.07-12.90) years, the mean (SD) annual rates of change were-1.53 (2.69) scale points on the MMSE, 1.44 (1.82) on the CDR-sb, and 2.55 (5.37) on the NPI. Among surviving participants, 30{\%} to 58{\%} progressed less than 1 point per year on these measures, even 5 to 7 years after dementia onset. Rates of change were correlated between MMSE and CDR-sb (r =-0.62, df = 201, p < 0.001) and between the CDR-sb and NPI (r = 0.20, df = 206, p < 0.004). Female subjects (LR χ2 = 8.7, df = 2, p = 0.013) and those with younger onset (likelihood ratio [LR] χ2 = 5.7, df = 2, p = 0.058) declined faster on the MMSE. Although one or more apolipoprotein E ε 4 alleles and ever use of FDA-approved antidementia medications were associated with initial MMSE scores, neither was related to the rate of progression in any domain. CONCLUSIONS: A significant proportion of persons with AD progresses slowly. The results underscore differences between population-based versus clinic-based samples and suggest ongoing need to identify factors that may slow the progression of AD.",
keywords = "Alzheimer dementia, Alzheimer disease, cognition, decline, dementia, neuropsychiatric symptoms, progression",
author = "Tschanz, {Joann T.} and Corcoran, {Chris D.} and Sarah Schwartz and Katherine Treiber and Green, {Robert C.} and Norton, {Maria C.} and Mielke, {Michelle M} and Kathleen Piercy and Martin Steinberg and Rabins, {Peter V.} and Leoutsakos, {Jeanne Marie} and Welsh-Bohmer, {Kathleen A.} and Breitner, {John C S} and Lyketsos, {Constantine G.}",
year = "2011",
month = "6",
doi = "10.1097/JGP.0b013e3181faec23",
language = "English (US)",
volume = "19",
pages = "532--542",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with alzheimer dementia

T2 - The cache county dementia progression study

AU - Tschanz, Joann T.

AU - Corcoran, Chris D.

AU - Schwartz, Sarah

AU - Treiber, Katherine

AU - Green, Robert C.

AU - Norton, Maria C.

AU - Mielke, Michelle M

AU - Piercy, Kathleen

AU - Steinberg, Martin

AU - Rabins, Peter V.

AU - Leoutsakos, Jeanne Marie

AU - Welsh-Bohmer, Kathleen A.

AU - Breitner, John C S

AU - Lyketsos, Constantine G.

PY - 2011/6

Y1 - 2011/6

N2 - OBJECTIVES: Progression of Alzheimer dementia (AD) is highly variable. Most estimates derive from convenience samples from dementia clinics or research centers where there is substantial potential for survival bias and other distortions. In a population-based sample of incident AD cases, we examined progression of impairment in cognition, function, and neuropsychiatric symptoms, and the influence of selected variables on these domains. DESIGN: Longitudinal, prospective cohort study. SETTING: Cache County (Utah). PARTICIPANTS: Three hundred twenty-eight persons with a diagnosis of possible/probable AD. MEASUREMENTS: Mini-Mental State Exam (MMSE), Clinical Dementia Rating sum-of-boxes (CDR-sb), and Neuropsychiatric Inventory (NPI). RESULTS: Over a mean follow-up of 3.80 (range: 0.07-12.90) years, the mean (SD) annual rates of change were-1.53 (2.69) scale points on the MMSE, 1.44 (1.82) on the CDR-sb, and 2.55 (5.37) on the NPI. Among surviving participants, 30% to 58% progressed less than 1 point per year on these measures, even 5 to 7 years after dementia onset. Rates of change were correlated between MMSE and CDR-sb (r =-0.62, df = 201, p < 0.001) and between the CDR-sb and NPI (r = 0.20, df = 206, p < 0.004). Female subjects (LR χ2 = 8.7, df = 2, p = 0.013) and those with younger onset (likelihood ratio [LR] χ2 = 5.7, df = 2, p = 0.058) declined faster on the MMSE. Although one or more apolipoprotein E ε 4 alleles and ever use of FDA-approved antidementia medications were associated with initial MMSE scores, neither was related to the rate of progression in any domain. CONCLUSIONS: A significant proportion of persons with AD progresses slowly. The results underscore differences between population-based versus clinic-based samples and suggest ongoing need to identify factors that may slow the progression of AD.

AB - OBJECTIVES: Progression of Alzheimer dementia (AD) is highly variable. Most estimates derive from convenience samples from dementia clinics or research centers where there is substantial potential for survival bias and other distortions. In a population-based sample of incident AD cases, we examined progression of impairment in cognition, function, and neuropsychiatric symptoms, and the influence of selected variables on these domains. DESIGN: Longitudinal, prospective cohort study. SETTING: Cache County (Utah). PARTICIPANTS: Three hundred twenty-eight persons with a diagnosis of possible/probable AD. MEASUREMENTS: Mini-Mental State Exam (MMSE), Clinical Dementia Rating sum-of-boxes (CDR-sb), and Neuropsychiatric Inventory (NPI). RESULTS: Over a mean follow-up of 3.80 (range: 0.07-12.90) years, the mean (SD) annual rates of change were-1.53 (2.69) scale points on the MMSE, 1.44 (1.82) on the CDR-sb, and 2.55 (5.37) on the NPI. Among surviving participants, 30% to 58% progressed less than 1 point per year on these measures, even 5 to 7 years after dementia onset. Rates of change were correlated between MMSE and CDR-sb (r =-0.62, df = 201, p < 0.001) and between the CDR-sb and NPI (r = 0.20, df = 206, p < 0.004). Female subjects (LR χ2 = 8.7, df = 2, p = 0.013) and those with younger onset (likelihood ratio [LR] χ2 = 5.7, df = 2, p = 0.058) declined faster on the MMSE. Although one or more apolipoprotein E ε 4 alleles and ever use of FDA-approved antidementia medications were associated with initial MMSE scores, neither was related to the rate of progression in any domain. CONCLUSIONS: A significant proportion of persons with AD progresses slowly. The results underscore differences between population-based versus clinic-based samples and suggest ongoing need to identify factors that may slow the progression of AD.

KW - Alzheimer dementia

KW - Alzheimer disease

KW - cognition

KW - decline

KW - dementia

KW - neuropsychiatric symptoms

KW - progression

UR - http://www.scopus.com/inward/record.url?scp=79958813690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958813690&partnerID=8YFLogxK

U2 - 10.1097/JGP.0b013e3181faec23

DO - 10.1097/JGP.0b013e3181faec23

M3 - Article

C2 - 21606896

AN - SCOPUS:79958813690

VL - 19

SP - 532

EP - 542

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

IS - 6

ER -